PMID- 3262691
OWN - NLM
STAT- MEDLINE
DCOM- 19881108
LR  - 20201214
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 91
IP  - 4
DP  - 1988 Oct
TI  - Ro(SS-A) positive Sjogren's/lupus erythematosus (SC/LE) overlap patients are 
      associated with the HLA-DR3 and/or DRw6 phenotypes.
PG  - 369-71
AB  - Ro(SS-A) positive female Sjogren's syndrome (SS) lupus erythematosus (LE) overlap 
      patients are a clinically and serologically homogeneous group generally 
      demonstrating prominent subacute cutaneous lupus erythematosus (SCLE) lesions, 
      cutaneous vasculitis, peripheral and central nervous system disease, pulmonary 
      disease, and a low frequency of glomerulonephritis. They commonly demonstrate 
      rheumatoid factor, hypergammaglobulinemia, antinuclear and Ro(SS-A) La(SS-B) 
      antibody activity. This study indicates that these patients are also 
      immunogenetically similar, sharing a statistically significant increased 
      frequency of HLA-B8, DR3, DRW6, DQ2, and DRw52. Sixty-three percent of these 
      SS/LE patients possess the extended haplotype (P-value 6.0 X 10(-3); RR 9.5) 
      HLA-B8, DR3, DQ2, DRw52. One hundred percent of this SS/LE cohort was DR3 or DRw6 
      (P-value less than or equal to 5.0 X 10(-3); relative risk 19.1). Fifty percent 
      of these patients were HLA DR3/DRw6 heterozygotes (P-value 1.5 X 10(-6); relative 
      risk 31.2). Thus, HLA-DR3 and DRw6 Ro(SS-A) positive SS/LE patients may possess a 
      similar, if not unique, DR region DNA nucleotide sequence involved in disease 
      susceptibility or immune regulation.
FAU - Provost, T T
AU  - Provost TT
AD  - Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 
      21205.
FAU - Talal, N
AU  - Talal N
FAU - Bias, W
AU  - Bias W
FAU - Harley, J B
AU  - Harley JB
FAU - Reichlin, M
AU  - Reichlin M
FAU - Alexander, E L
AU  - Alexander EL
LA  - eng
GR  - AM34159/AM/NIADDK NIH HHS/United States
GR  - R01 AM25650/AM/NIADDK NIH HHS/United States
GR  - R01 AM30487/AM/NIADDK NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Autoantigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR3 Antigen)
RN  - 0 (HLA-DR6 Antigen)
RN  - 0 (RNA, Small Cytoplasmic)
RN  - 0 (RO60 protein, human)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (SS-A antigen)
SB  - IM
MH  - Autoantigens/*analysis
MH  - Female
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DR3 Antigen
MH  - HLA-DR6 Antigen
MH  - Haplotypes
MH  - Heterozygote
MH  - Humans
MH  - Lupus Erythematosus, Systemic/genetics/*immunology
MH  - Phenotype
MH  - *RNA, Small Cytoplasmic
MH  - *Ribonucleoproteins
MH  - Risk Factors
MH  - Sjogren's Syndrome/genetics/*immunology
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - S0022-202X(88)91844-1 [pii]
AID - 10.1111/1523-1747.ep12476204 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1988 Oct;91(4):369-71. doi: 10.1111/1523-1747.ep12476204.